Following detailed investigation of the trans-acting transcription factors regulating Prm1/TPα and Prm3/TPβ in PCa settings, interrogation of the CpG methylation status of the TBXA2R might also serve as a key clinical marker with which to stratify higher risk patients and to tailor treatment options. This evidence concerns the gene PRM1 and posterior cortical atrophy.